Phase I safety and pharmacokinetic dose-escalation study of pilaralisib polymorph E, a phosphoinositide 3-kinase inhibitor in tablet formulation, in patients with solid tumors or lymphoma

2016 ◽  
Vol 78 (1) ◽  
pp. 83-90
Author(s):  
Oliver E. Bechter ◽  
Herlinde Dumez ◽  
Jo Costermans ◽  
Kevin Punie ◽  
Karl Hsu ◽  
...  
Keyword(s):  
Phase I ◽  
Solid Tumors ◽  
Dose Escalation ◽  
Kinase Inhibitor ◽  
Tablet Formulation ◽  
Dose Escalation Study ◽  
Phosphoinositide 3 Kinase

Phase I dose-escalation study of the SRC and multi-kinase inhibitor BMS-354825 in patients (pts) with GIST and other solid tumors

2005 ◽  
Vol 23 (16_suppl) ◽  
pp. 3034-3034 ◽  
Author(s):  
T. R. J. Evans ◽  
J. A. Morgan ◽  
A. D. van den Abbeele ◽  
I. R. J. McPherson ◽  
S. George ◽  
...  
Keyword(s):  
Phase I ◽  
Solid Tumors ◽  
Dose Escalation ◽  
Kinase Inhibitor ◽  
Dose Escalation Study

Phase I dose-escalation study of E7080, a selective tyrosine kinase inhibitor, administered orally to patients with solid tumors.

2010 ◽  
Vol 28 (15_suppl) ◽  
pp. 2540-2540 ◽  
Author(s):  
D. S. Hong ◽  
B. S. Koetz ◽  
R. Kurzrock ◽  
N. N. Senzer ◽  
W. Hanekom ◽  
...  
Keyword(s):  
Tyrosine Kinase ◽  
Phase I ◽  
Tyrosine Kinase Inhibitor ◽  
Solid Tumors ◽  
Dose Escalation ◽  
Kinase Inhibitor ◽  
Dose Escalation Study
Sign in / Sign up

Export Citation Format

Share Document